Use of varicella vaccines to prevent herpes zoster in older individuals
It is likely that the frequency and severity of herpes zoster in older people is the result of an age-related decline in varicella-zoster virus-specific T-cell mediated immunity. Numerous trials of vaccines to boost these responses have demonstrated their safety and immunogenicity. Both live attenuated and inactivated vaccines have been studied. Persistence of booster responses is dose-related, and the half-life of some boosted measures of T-cell mediated immunity exceeds 5 years. Although these trials have been hampered by uncertainty about the critical immune responses to evaluate, the stage is set for a double-blind, placebo-controlled trial of sufficient size to determine efficacy. Such a trial is now underway.
KeywordsHerpes Zoster Varicella Vaccine Bone Marrow Transplant Recipient Lymphocyte Proliferation Assay Booster Response
Unable to display preview. Download preview PDF.
- 6.Berger R, Luescher D, Just M (1985) Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination. Postgrad Med J Postgrad Med J: 61: 143–145Google Scholar
- 17.Hayward AR, Buda K, Jones M, White CJ, Levin MJ (1996) VZV specific cytotoxicity following secondary immunization with live or killed vaccine. Clin Immunol 9: 241–245Google Scholar
- 20.Hayward AR, Pontesilli O, Herberger, Laszlo M, Levin M (1986) Specific lysis of VZV infected B lymphoblasts by human T cells. J Virol 65: 179–184Google Scholar
- 25.Levin MJ, Barber D, Goldblatt E, Jones M, La Fleur B, Chan C, Stinson D, Zerbe GO, Hayward AR (1998) Use of live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect. J Infect Dis 178 [Suppl 1]: S109—S112PubMedCrossRefGoogle Scholar
- 25a.Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, Jones M, Hayward AR (2000) Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 18: 2915–2920PubMedCrossRefGoogle Scholar
- 31.Rogers RS III, Tindall JP (1971) Geriatric herpes zoster. J Am Geriar Soc 19: 495–504Google Scholar
- 34.Starr SE, Tinklepaugh C, Bocks E, Miller D, Rudenstein M, Plotkin SA (1987) Immunization of healthy seropositive middle aged and elderly adults with varicella-zoster virus (VZV) vaccine. (abstract no. 1237). In Programs and Abstracts of the Twenty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, p 313Google Scholar